AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Asthma
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT02967159
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT02962960
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet
Phase 1
Completed
- Conditions
- High Risk Coronary Artery Disease
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT02963116
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China
Completed
- Conditions
- Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT02955316
- Locations
- 🇨🇳
Research Site, Wuhan, Hubei, China
A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9
- Registration Number
- NCT02950805
- Locations
- 🇺🇸
Research Site, Chapel Hill, North Carolina, United States
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Phase 2
Completed
- Conditions
- Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02937818
- Locations
- 🇺🇦
Research Site, Sumy, Ukraine
A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers
Phase 1
Completed
- Conditions
- Study is Being Conducted in Healthy Volunteers
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT02934607
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)
Phase 1
Completed
- Conditions
- Male Subjects With Type II Diabetes (T2DM)
- Interventions
- Drug: AZD8601+Placebo (SAD)Drug: AZD8601+PlaceboDrug: Placebo+Placebo
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT02935712
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Gefitinib Long-term Survivor Study
Terminated
- Conditions
- EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT02932345
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers
Phase 1
Completed
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Treatment C - AZD7594Drug: Treatment A - AZD7594Drug: Treatment B - AZD7594
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT02928354
- Locations
- 🇩🇪
Research Site, Berlin, Germany